# Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry – FDA Guidance

Source: https://www.keypedia.com/guidances/guidance-document/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-draft-guidance-for-industry/4c570099-1582-4019-8f81-d0260a2e984c

> FDA guidance document: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry. Issue date: September 24, 2025. Get complete insights and analysis.

---

## Details

- Title: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Biologics Evaluation and Research
- Office URL: /offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d
- Issue Date: 2025-09-24
- Last Changed: 2025-09-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-D-6159">FDA-2017-D-6159</a>

## Related Documents

- [Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management](https://www.keypedia.com/guidances/guidance-document/individualized-human-genome-editing-products-considerations-for-bla-submission-and-postapproval-management/bd746678-d2ab-441f-b005-7065f4f7a403)
- [Potency Assessment of Active Immunotherapy Products](https://www.keypedia.com/guidances/guidance-document/potency-assessment-of-active-immunotherapy-products/c0c49725-86ec-40cb-a98f-19549a1dd4e7)
- [Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing](https://www.keypedia.com/guidances/guidance-document/safety-assessment-of-genome-editing-in-human-gene-therapy-products-using-next-generation-sequencing/8bd86906-9b70-4e40-ae4a-dde0c1ea99ca)